Sigma Planning’s Grace Therapeutics GRCE Stock Holding History
Bought
Maintained
Sold
Other funds holding GRCE
Sigma Planning's GRCE Position: Q4 2019 in Review
Sigma Planning sold out of Grace Therapeutics (GRCE) in Q4 2019, closing a stake of 215 shares — an estimated $19K sold.
Sigma Planning first reported a position in GRCE in Q3 2019 and held it in 1 quarter. The position peaked at $19K in Q3 2019. 33 funds tracked by Wall St. Rank hold GRCE as of Q4 2019.
- Sigma Planning reported no remaining Grace Therapeutics position as of Q4 2019 after selling out during the quarter.
- Sigma Planning sold 215 Grace Therapeutics shares in Q4 2019, an estimated $19K.
- Sigma Planning first reported a position in Grace Therapeutics in Q3 2019 and held it in 1 quarter.
- Sigma Planning's Grace Therapeutics position peaked at $19K in Q3 2019.
- 33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q4 2019.
Based on Sigma Planning's 13F filing for Q4 2019, filed 3 Feb 2020.